175 related articles for article (PubMed ID: 10955852)
1. Morphine antinociception is enhanced in mdr1a gene-deficient mice.
Zong J; Pollack GM
Pharm Res; 2000 Jun; 17(6):749-53. PubMed ID: 10955852
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test.
Lötsch J; Tegeder I; Angst MS; Geisslinger G
Life Sci; 2000 May; 66(24):2393-403. PubMed ID: 10864101
[TBL] [Abstract][Full Text] [Related]
3. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
Dagenais C; Zong J; Ducharme J; Pollack GM
Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
[TBL] [Abstract][Full Text] [Related]
4. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.
Chen C; Pollack GM
J Pharmacol Exp Ther; 1998 Nov; 287(2):545-52. PubMed ID: 9808679
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
[TBL] [Abstract][Full Text] [Related]
7. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Shen J; Carcaboso AM; Hubbard KE; Tagen M; Wynn HG; Panetta JC; Waters CM; Elmeliegy MA; Stewart CF
Cancer Res; 2009 Jul; 69(14):5885-92. PubMed ID: 19567673
[TBL] [Abstract][Full Text] [Related]
8. Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.
Kalvass JC; Graff CL; Pollack GM
Pharm Res; 2004 Oct; 21(10):1867-70. PubMed ID: 15553234
[TBL] [Abstract][Full Text] [Related]
9. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
10. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice.
Hamabe W; Maeda T; Fukazawa Y; Kumamoto K; Shang LQ; Yamamoto A; Yamamoto C; Tokuyama S; Kishioka S
Pharmacol Biochem Behav; 2006 Nov; 85(3):629-36. PubMed ID: 17134744
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice.
Pereira de Oliveira M; Garcion E; Venisse N; Benoit JP; Couet W; Olivier JC
Pharm Res; 2005 Nov; 22(11):1898-1905. PubMed ID: 16132350
[TBL] [Abstract][Full Text] [Related]
13. Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.
Hassan HE; Myers AL; Coop A; Eddington ND
J Pharm Sci; 2009 Dec; 98(12):4928-40. PubMed ID: 19370547
[TBL] [Abstract][Full Text] [Related]
14. Variable modulation of opioid brain uptake by P-glycoprotein in mice.
Dagenais C; Graff CL; Pollack GM
Biochem Pharmacol; 2004 Jan; 67(2):269-76. PubMed ID: 14698039
[TBL] [Abstract][Full Text] [Related]
15. Uptake and efflux of the peptidic delta-opioid receptor agonist.
Dagenais C; Ducharme J; Pollack GM
Neurosci Lett; 2001 Apr; 301(3):155-8. PubMed ID: 11257421
[TBL] [Abstract][Full Text] [Related]
16. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.
Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
Pharm Res; 1998 Apr; 15(4):599-605. PubMed ID: 9587957
[TBL] [Abstract][Full Text] [Related]
17. Spinal interaction between the highly selective μ agonist DAMGO and several δ opioid receptor ligands in naive and morphine-tolerant mice.
Szentirmay AK; Király KP; Lenkey N; Lackó E; Al-Khrasani M; Friedmann T; Timár J; Gyarmati S; Tóth G; Fürst S; Riba P
Brain Res Bull; 2013 Jan; 90():66-71. PubMed ID: 22995282
[TBL] [Abstract][Full Text] [Related]
18. Effect of Subchronic Intravenous Morphine Infusion and Naloxone-Precipitated Morphine Withdrawal on P-gp and Bcrp at the Rat Blood-Brain Barrier.
Chaves C; Gómez-Zepeda D; Auvity S; Menet MC; Crété D; Labat L; Remião F; Cisternino S; Declèves X
J Pharm Sci; 2016 Jan; 105(1):350-8. PubMed ID: 26554626
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.
Chen C; Pollack GM
Pharm Res; 1999 Feb; 16(2):296-301. PubMed ID: 10100317
[TBL] [Abstract][Full Text] [Related]
20. Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.
Cisternino S; Rousselle C; Dagenais C; Scherrmann JM
Pharm Res; 2001 Feb; 18(2):183-90. PubMed ID: 11405289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
